Tracon Pharmaceuticals, Inc. financial data

Location
San Diego, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q2 2024 - 13 Aug 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 77% % 6.2%
Return On Equity -238% % -177%
Return On Assets 57% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3,407,564 shares -89%
Common Stock, Shares, Outstanding 3,407,564 shares -87%
Common Stock, Value, Issued $3,000 USD -89%
Weighted Average Number of Shares Outstanding, Basic 3,008,090 shares 88%
Weighted Average Number of Shares Outstanding, Diluted 3,008,090 shares 88%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $55,000 USD -99%
Research and Development Expense $7,048,000 USD -57%
General and Administrative Expense $5,457,000 USD -36%
Operating Income (Loss) $7,305,000 USD 64%
Nonoperating Income (Expense) $12,500,000 USD
Net Income (Loss) Attributable to Parent $5,195,000 USD 55%
Earnings Per Share, Basic 8 USD/shares 76%
Earnings Per Share, Diluted 8 USD/shares 76%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $6,270,000 USD 261%
Cash, Cash Equivalents, and Short-term Investments $6,300,000 USD 232%
Assets, Current $6,510,000 USD -41%
Property, Plant and Equipment, Net $30,000 USD -32%
Assets $7,400,000 USD -39%
Accounts Payable, Current $2,652,000 USD
Employee-related Liabilities, Current $416,000 USD -60%
Accrued Liabilities, Current $6,823,000 USD
Liabilities, Current $9,891,000 USD -63%
Other Liabilities, Noncurrent $598,000 USD -30%
Retained Earnings (Accumulated Deficit) $246,506,000 USD 2.1%
Stockholders' Equity Attributable to Parent $3,089,000 USD 80%
Liabilities and Equity $7,400,000 USD -39%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $2,543,000 USD 49%
Net Cash Provided by (Used in) Financing Activities $1,870,000 USD
Common Stock, Shares Authorized 60,000,000 shares 0%
Common Stock, Shares, Issued 3,407,564 shares -87%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $673,000 USD 94%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $6,343,000 USD 238%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $4,000 USD 0%
Share-based Payment Arrangement, Expense $1,705,000 USD -12%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%